Literature DB >> 22803772

Impact of traits of metabolic syndrome on β-cell function and insulin resistance in normal fasting, normal glucose tolerant subjects.

Luigi X Cubeddu1, Irene S Hoffmann.   

Abstract

OBJECTIVE: Metabolic syndrome, impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) predict risk for type 2 diabetes mellitus (T2DM). To determine if increased risk preceded development of these abnormalities, β-cell function and insulin resistance were assessed in euglycemic subjects with and without traits of metabolic syndrome.
METHODS: A total of 562 apparently healthy Latin-American subjects were screened for metabolic syndrome [National Education Cholesterol Program Adult Treatment Panel III (NECP ATP III)]. Early pancreatic insulin response ΔInsulin(0-30)/ΔGlucose(0-30), Matsuda index, disposition index (DI), and homeostasis model assessment of insulin resistance (HOMA-IR) ratio were obtained from oral glucose tolerance testing (0-180 min).
RESULTS: ΔI(0-30)/ΔG(0-30), Matsuda index, DI, and HOMA-IR deteriorated in direct proportion with number of traits of metabolic syndrome, and with increases in glucose levels within the euglycemic range. DI was the most sensitive index. In subjects with 1, 2, 3, and 4-5 traits, DI was 21.4%, 40%, 57%, and 76% lower, respectively, than in subjects with no traits. As a single trait, abdominal obesity was associated with insulin resistance, whereas, low high-density lipoprotein cholesterol (HDL-C), alone or combined with high triglycerides, was not associated with insulin resistance or β-cell dysfunction. Combined impairments in β-cell function and insulin sensitivity were responsible for the increases in fasting and 2-h plasma glucose concentrations within the euglycemic range.
CONCLUSIONS: Impaired β-cell function and increased insulin resistance are present much before development of metabolic syndrome, IFG, or IGT. β-Cell function and insulin sensitivity worsen in direct proportion with number of traits of metabolic syndrome and increases in glucose levels. Compared to abdominal obesity, low HDL-C±high triglycerides may bear a lesser weight in predicting risk of T2DM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22803772     DOI: 10.1089/met.2012.0040

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  5 in total

1.  β-Cell dysfunction is associated with metabolic syndrome severity in adults.

Authors:  Steven K Malin; Stephen Finnegan; Ciaran E Fealy; Julianne Filion; Michael B Rocco; John P Kirwan
Journal:  Metab Syndr Relat Disord       Date:  2013-11-27       Impact factor: 1.894

2.  Impaired PI3 K Akt expression in liver and skeletal muscle of ovariectomized rats.

Authors:  Yan Wang; Baoxin Li; Wei Zhang; Yan Liu; Peng Xue; Jianxia Ma; Yukun Li
Journal:  Endocrine       Date:  2013-02-02       Impact factor: 3.633

3.  The Relationship of Metabolic Syndrome Traits with Beta-Cell Function and Insulin Sensitivity by Oral Minimal Model Assessment in South Asian and European Families Residing in the Netherlands.

Authors:  Thekla Geragotou; Sjaam Jainandunsing; Behiye Özcan; Felix W M de Rooij; Alexander Kokkinos; Nicholas Tentolouris; Eric J G Sijbrands
Journal:  J Diabetes Res       Date:  2016-08-11       Impact factor: 4.011

4.  The Metabolic Syndrome: Emerging Novel Insights Regarding the Relationship between the Homeostasis Model Assessment of Insulin Resistance and other Key Predictive Markers in Young Adults of Western Algeria.

Authors:  Mohammed Ilyes Belhayara; Zoheir Mellouk; Mohammed Seddik Hamdaoui; Malika Bachaoui; Omar Kheroua; Willy J Malaisse
Journal:  Nutrients       Date:  2020-03-10       Impact factor: 5.717

5.  Higher Ratio of Abdominal Subcutaneous to Visceral Adipose Tissue Related with Preservation of Islet β-Cell Function in Healthy Individuals.

Authors:  Juan Liu; Jianbin Liu; Hai Li; Liehua Liu; Jing Zheng; Zhimin Huang; Xiaopei Cao; Haipeng Xiao; Yanbing Li
Journal:  Int J Endocrinol       Date:  2017-12-28       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.